Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.47 |
| ▸ | METAP2 | P50579 | 8/20 | 0.45 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.43 |
| ▸ | CKS1B | P61024 | 2/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | CCR9 | P51686 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3978587 | 0.87 | ALDH1A1 (0.55) | SLC22A12METAP2METAP1ALDH1A1GAA | |
| SCHEMBL3985897 | 0.83 | METAP2 (0.47) | METAP2SLC40A1CKS1BSKP2GLO1 | |
| SCHEMBL4272722 | 0.79 | METAP2 (0.69) | METAP2SLC40A1GLO1 | |
| SCHEMBL3983177 | 0.78 | METAP2 (0.67) | CYP3A4CYP2C9METAP2SLC40A1CKS1B | |
| SCHEMBL3985666 | 0.72 | TP53 (0.48) | SLC22A12METAP2METAP1ALDH1A1GAA | |
| SCHEMBL16496135 | 0.70 | ACLY (0.58) | METAP2SLC40A1CKS1BSKP2GLO1 | |
| SCHEMBL18299151 | 0.70 | ALDH1A1 (0.50) | SLC22A12METAP2SLC40A1ALDH1A1GAA | |
| SCHEMBL790693 | 0.69 | SLC40A1 (0.59) | SLC40A1CKS1BSKP2GLO1ALDH1A1 | |
| SCHEMBL3979712 | 0.68 | TP53 (0.47) | CKS1BSKP2ALDH1A1 | |
| SCHEMBL3981261 | 0.68 | ALDH1A1 (0.58) | METAP2SLC40A1METAP1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491718-B2 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES (US) | 2009-02-17 | — | — | US | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | CYP3A4 4067/4885CYP2C9 3961/4885SLC22A12 499/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | CYP3A4 4067/4885CYP2C9 3961/4885SLC22A12 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.